(PharmaNewsWire.Com, September 29, 2017 ) Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.
Report Highlights
Publisher's Pharmaceutical and Healthcare latest pipeline guide Dyskinesia-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 13, 4, 17 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.
Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
List of Tables Number of Products under Development for Dyskinesia, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Dyskinesia-Pipeline by Adamas Pharmaceuticals Inc, H2 2017 Dyskinesia-Pipeline by Addex Therapeutics Ltd, H2 2017 Dyskinesia-Pipeline by Advicenne SA, H2 2017 Dyskinesia-Pipeline by Avanir Pharmaceuticals Inc, H2 2017 Dyskinesia-Pipeline by Bionomics Ltd, H2 2017 Dyskinesia-Pipeline by Catalyst Biosciences Inc, H2 2017 Dyskinesia-Pipeline by Cavion LLC, H2 2017 Dyskinesia-Pipeline by Clevexel Pharma SAS, H2 2017 Dyskinesia-Pipeline by EpiVax Inc, H2 2017 Dyskinesia-Pipeline by Heptares Therapeutics Ltd, H2 2017 Dyskinesia-Pipeline by Ipsen SA, H2 2017 Dyskinesia-Pipeline by Merz Pharma GmbH & Co KgaA, H2 2017 Dyskinesia-Pipeline by Neurim Pharmaceuticals Ltd, H2 2017 Dyskinesia-Pipeline by Neurocrine Biosciences Inc, H2 2017 Dyskinesia-Pipeline by Neurolixis Inc, H2 2017 Dyskinesia-Pipeline by Osmotica Pharmaceutical Corp, H2 2017 Dyskinesia-Pipeline by Phenomenome Discoveries Inc, H2 2017 Dyskinesia-Pipeline by Sage Therapeutics Inc, H2 2017 Dyskinesia-Pipeline by SciFluor Life Sciences LLC, H2 2017 Dyskinesia-Pipeline by SOM Biotech SL, H2 2017 Dyskinesia-Pipeline by Synchroneuron Inc, H2 2017 Dyskinesia-Dormant Projects, H2 2017 Dyskinesia-Dormant Projects, H2 2017 (Contd..1), H2 2017 Dyskinesia-Discontinued Products, H2 2017
List of Figures Number of Products under Development for Dyskinesia, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Number of Products by Top 10 Targets, H2 2017 Number of Products by Stage and Top 10 Targets, H2 2017 Number of Products by Top 10 Mechanism of Actions, H2 2017 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Molecule Types, H2 2017 Number of Products by Stage and Molecule Types, H2 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
